Distinct profiles of multiple co-occurring symptoms in patients with gastrointestinal cancers receiving chemotherapy

• Published in: Supportive care in cancer 2021-08, Vol.29 (8), p.4461-4471
• Main Authors: Lin, Yufen, Bailey, Donald E., Docherty, Sharron L., Porter, Laura S., Cooper, Bruce A., Paul, Steven M., Kober, Kord M., Hammer, Marilyn J., Wright, Fay, Dunn, Laura B., Conley, Yvette P., Levine, Jon D., Miaskowski, Christine
• Format: Article
• Language: English
• Subjects: Analysis; Backache; Cancer; Cancer patients; Care and treatment; Chemotherapy; Comorbidity; Demographics; Gastric cancer; Gastrointestinal cancer; Latent class analysis; Medical colleges; Medical research; Medicine; Medicine & Public Health; Medicine, Experimental; Mental depression; Nursing; Nursing Research; Oncology; Original Article; Pain; Pain Medicine; Quality of life; Rehabilitation Medicine; Risk factors
• ISSN: 0941-4355; 1433-7339
• DOI: 10.1007/s00520-020-05946-4

Purpose Identify subgroups of gastrointestinal (GI) cancer patients with distinct multiple co-occurring symptom profiles and evaluate for differences among these subgroups in demographic and clinical characteristics and quality of life (QOL) outcomes. Methods Patients with GI cancers ( n = 399) completed the Memorial Symptom Assessment Scale (MSAS) that was used to assess for multiple co-occurring symptoms. Latent class analysis (LCA) was used to identify subgroups of patients with distinct symptom profiles using symptom occurrence ratings. Differences in demographic and clinical characteristics and QOL outcomes among the subgroups were evaluated using parametric and nonparametric tests. Results All Low (36.6%), Moderate (49.4%), and All High (14.0%) classes were identified. Compared to the All Low class, patients in the other two classes were significantly younger and were more likely to report depression and back pain. Compared to the other two classes, patients in the All High class had fewer years of education and a higher number of comorbidities. Significant differences were found among the three classes for comorbidity burden and total number of MSAS symptoms (i.e., All Low < Moderate < All High), as well as for performance status (i.e., All Low > Moderate > All High). A higher symptom burden was associated with poorer QOL outcomes. Conclusions The first study to identify subgroups of patients with GI cancers based on distinct symptom profiles. LCA allowed for the identification of risk factors associated with a higher symptom burden. Clinicians can use this information to identify high-risk patients and develop personalized symptom management interventions.